TITLE

ESF-EMBO symposium "molecular biology and innovative therapies in sarcomas of childhood and adolescence" Sept 29-Oct 4, Polonia Castle Pultusk, Poland

AUTHOR(S)
Schäfer, Beat W.; Koscielniak, Ewa; Kovar, Heinrich; Fulda, Simone
PUB. DATE
June 2013
SOURCE
Frontiers in Oncology;Jun2013, Vol. 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) are among the most common pediatric sarcomas (Arndt et al., 2012). Despite sarcomas representing a highly heterogeneous group of tumors, ES and alveolar RMS (ARMS) typically share one common genetic characteristic, namely a specific chromosomal translocation (Helman and Meltzer, 2003; Lessnick and Ladanyi, 2012).These translocations generate fusion proteins, which are composed of two transcription factors (TF).Typically, oneTF is a developmentally regulated factor that is essential for proper specification of a given lineage and provides the DNA-binding domain, while the partner TF contributes a transactivation domain that drives aberrant expression of target genes. Based on these common genetic characteristics, the first ESF-EMBO research conference entitled "Molecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence" with special focus on RMS and ES was held at the Polonia Castle in Pultusk, Poland. The conference gathered 70 participants from more than 15 countries and several continents representing most research groups that are active in this field.
ACCESSION #
88067196

 

Related Articles

  • Potential molecular targets for Ewing's sarcoma therapy. Babu, Jully; Thangarajan, Rajkumar // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2012, Vol. 33 Issue 4, p195 

    Ewing's sarcoma (ES) is a highly malignant tumor of children and young adults. Modern therapy for Ewing's sarcoma combines high-dose chemotherapy for systemic control of disease, with advanced surgical and/or radiation therapeutic approaches for local control. Despite optimal management, the...

  • Bilateral endoprosthetic replacements of the proximal femur. Foukas, Athanasios F.; Grimer, Robert J. // Sarcoma;Mar1998, Vol. 2 Issue 1, p49 

    Patient . We report the case of a 20-year-old caucasian male with an Ewing's sarcoma in the left upper femur. After induction chemotherapy, he underwent resection of the left upper femur and insertion of a cemented proximal femoral replacement. Four years later, he presented with a solitary bone...

  • Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of... Toretsky, Jeffrey A.; Neckers, Leonard // JNCI: Journal of the National Cancer Institute;3/1/95, Vol. 87 Issue 5, p385 

    Evaluates whether t(11;12)-positive cells would be detected in peripheral blood progenitor cell collections and if they would disappear with treatment of Ewing's sarcoma. Monitoring of patients whose tumors contain a translocation from minimal residual disease; Bone marrow biopsies required...

  • Dose-escalating alkylating agents in Ewing's sarcoma family of tumors: no improvement in outcome.  // Hem/Onc Today;5/25/2009, Vol. 10 Issue 10, p27 

    The article discusses research on the effect of dose-intensified regimen of vincristine, cyclophosphamide and doxorubicin (VDC) alternating with ifosfamide and etoposide (IE) on survival or outcome among patients with nonmetastatic Ewing's sarcoma family of tumors, conducted by L. Granowetter et...

  • Progress in the molecular biology of Ewing tumors. Kovar, Heinrich // Sarcoma;Mar1998, Vol. 2 Issue 1, p3 

    Purpose/results/discussion . Rearrangement of the EWS gene with an ETS oncogene by chromosomal translocation is a hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor specificity and variability of this aberration have been matters of intense investigation in recent...

  • APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells. Peters, Haley L.; Ying Yan; Solheim, Joyce C. // OncoImmunology;Oct2013, Vol. 2 Issue 10, pe26293-1 

    Ewing's sarcoma (EWS) is a pediatric cancer that is conventionally treated by surgery, chemotherapy, and radiation therapy. Innovative immunotherapies to treat EWS are currently under development. Unfortunately for EWS patients, when the disease is found to be resistant to current therapeutic...

  • Targeted Therapy in Ewing Sarcoma. Lissat, A.; Chao, M. M.; Kontny, U. // ISRN Oncology;2012, p1 

    Despite marked improvement in the prognosis of patients with nonmetastatic Ewing sarcoma (ES), the outcome for patients with recurrent or metastatic disease remains poor. Insight into key biologic processes in ES could provide new therapeutic targets. The particular biologic feature of ES, the...

  • CANCER PATIENT REFERRALS.  // Clinical Pediatrics;Jun1984, Vol. 23 Issue 6, p341 

    Reports that the Pediatric Branch of the National Cancer Institute is studying and treating children with cancer, including leukemia, non-Hodgkin's lymphoma, Ewing's sarcoma, neuroblastoma, rhabdomyosarcoma and osteogenic sarcoma. Ability of the Pediatric Branch to provide a second opinion...

  • Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner. Wagner, Lars // Current Cancer Therapy Reviews;2010, Vol. 6 Issue 4, p283 

    Irinotecan has been increasingly used for treatment of pediatric cancers over the past decade. Irinotecan has modest single-agent activity against common childhood solid tumors, and the low incidence of myelosuppression seen with protracted administration makes it well-suited for combination...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics